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Summary 
 
Background and Purpose: In this study we used adenovirus infection to over-
express the dual specific phosphatase, MAP kinase phosphatase-2 (MKP-2), in human 
umbilical vein endothelial cells and examined inflammatory protein expression and 
apoptosis, two key features of endothelial dysfunction in disease.   
Experimental approaches: We generated an adenoviral version of MKP-2 
(Adv.MKP-2) and infected HUVECs for 40 h.  TNF! stimulated MAP kinase 
phosphorylation and protein expression was measured by Western blotting.  Cellular 
apoptosis was assayed by FACS.   
Key results: Infection with Adv.MKP-2 selectively abolished TNF!-mediated JNK 
activation and had little effect upon ERK or p38 MAP kinase.  Adv.MKP-2 abrogated 
COX-2 expression whilst induction of the endothelial cell adhesion molecules ICAM 
and VCAM, two NF"B-dependent proteins, were not affected.   However, when 
ICAM and VCAM expression was partly reduced by blockage of the NF"B pathway 
Adv.MKP-2 was able to reverse this inhibition.  This correlated with enhanced 
TNF!-induced I"B! loss, a marker of NF"B activation. TNF! in combination with 
NF"B blockade also increased HUVEC apoptosis; this was significantly reversed by 
Adv.MKP-2. Protein markers of cellular damage and apoptosis, H2AX 
phosphorylation and caspase-3 cleavage, were also reversed by MKP-2 over-
expression.  
Conclusions: These results show that over-expression of MKP-2 has differential 
effects upon the expression of inflammatory proteins due to a reciprocal effect upon 
JNK and NF"B signalling and is also able to prevent TNF! mediated endothelial cell 
death.  These properties may make Adv.MKP-2 a potentially useful future therapy in 
cardiovascular diseases were endothelial dysfunction is a feature.  
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Abbreviations: 
HUVECs, human umbilical vein endothelial cells; MKP-2, MAP kinase phosphatase-
2, JNK; c-Jun-N-terminal kinase, IKK, inhibitory kappa B kinase; Adv., adenovirus, 
ICAM, inter-cellular adhesion molecule; VCAM, vascular cell adhesion molecule;  
TNF!, Tumour necrosis factor alpha.  
 
Introduction 
It is now accepted that perturbation in normal endothelial cell function is a key 
initiator of cardiovascular disease including atherosclerosis, renal failure and diabetes 
(Cines et al., 1998; Esper et al., 2006).  Endothelial cells activated by factors such as 
cytokines, free radicals and hypoxia increase the expression of a number of pro-
inflammatory proteins such as IL-6 and MCP-1, COX-2 which produces 
prostaglandins, and adhesion molecules such as E-selectin, ICAM and VCAM.  This 
results in a functional shift towards reduced vasodilatation and a pro-inflammatory 
state (Esper et al., 2006).  In addition, endothelial cell apoptosis is also implicated in a 
number of cardiovascular conditions.  This includes atherosclerosis (Rossig et al., 
2001; Tricot et al., 2000), myocardial ischaemia (Scarabelli et al., 2001; Scarabelli et 
al., 2002; Zhao et al., 2009), heart failure (Rossig et al., 2000) and lower limb 
ischaemia (Xie et al., 2006).  Pharmacological approaches to prevent either of these 
events may therefore be of benefit in certain disease conditions.  
The mitogen-activated protein (MAP) kinases play key roles in the regulation 
of endothelial cell function through phosphorylation of a number of cytosol and 
nuclear targets (Yu et al., 2007).  There are three main families of MAP kinases; the 
extracellular regulated kinases (ERKs), the p38 MAP kinases and the c-Jun N-
terminal kinases (JNKs). Whilst ERK is associated with endothelial cell survival 
(Mavria et al., 2006; Pintus et al., 2003; Yu et al., 1999), both p38 MAP kinase and 
JNK are strongly associated with inflammation and endothelial cell apoptosis 
(Nakagami et al., 2001; Wadgaonkar et al., 2004).  Whilst JNK is linked to 
expression of COX-2, and E-selectin (Min et al., 1997; Naderer et al., 2008; 
Nakagami et al., 2001), a larger body of evidence implicates JNK in the regulation of 
cell death (Sabapathy et al., 1999; Tournier et al., 2000). In endothelial cells, JNK is 
associated with apoptosis mediated by agents such as cytokines, hydrogen peroxide 
(Wang et al., 1999) and high glucose concentration (Ho et al., 2000).   Recently the 
JNK inhibitor SP600125 (Bennett et al., 2001) have been shown to reverse apoptosis 
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in endothelial cells (Fu et al., 2006; Karahashi et al., 2009), however, SP600125 may 
not be as selective as first indicated (Cameron et al., 2003). Thus, novel approaches to 
selectively inhibit JNK activation in endothelial cells could be useful.     
Thus, in an attempt to negatively regulate JNK activity and prevent endothelial 
cell inflammation and death, we developed an adenoviral version of mitogen-
activated protein kinase phosphatase-2 (MKP-2), (Misra-Press et al., 1995).  MKP-2 
is a member of the dual specific phosphatase family, (Keyse, 2008) which functions 
to dephosphorylate the mitogen-activated protein (MAP) kinases.  It is nuclear 
targeted due to the presence of two nuclear location sequences (Sloss et al., 2005) and 
although specific for ERK and JNK in vitro (Chu et al., 1996), we have demonstrated 
selectivity for JNK in a number of cell systems (Cadalbert et al., 2005; Robinson et 
al., 2001).  We used this adenovirus to over-express MKP-2 in endothelial cells and 
determine the profile of kinase inhibition and the effect upon a number of end points 
associated with endothelial cell activation.  In this study we show that over-expression 
of MKP-2 abolished JNK activity in HUVECs and abrogated COX-2 expression in 
response to TNF!. In contrast, ICAM and VCAM expression were not affected by 
Adv.MKP-2.  However, when ICAM and VCAM expression was reduced by blocking 
the NF"B pathway, MKP-2 partly reversed inhibition of ICAM and VCAM 
expression. This effect correlated with enhanced I"B! loss, indicative of cross talk 
regulation of the NF"B pathway by MKP-2.  Apoptosis induced by TNF! in 
combination with NF"B blockage, was also inhibited following Adv.MKP-2 
expression.  This effect correlated with a reduction in the phosphorylation of the 
nuclear protein H2AX and cleavage of caspase-3, a cytosolic effector caspase of the 
apoptosis pathway.  These data suggests that MKP-2 may be a useful mode of therapy 
in conditions were endothelial cell apoptosis is a feature, not only by inhibiting JNK 
signalling, but by enhancing NF"B activation.  We also show for the first time that 
MKP-2 can regulate cytosolic initiated apoptotic signalling events despite being a 
nuclear enzyme.   
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Methodology  
 
Reagents 
All reagents were from Sigma (Poole UK), unless otherwise stated. Tumour necrosis 
factor-! (TNF-!) was obtained from Santa Cruz Biotechnology (CA, USA). 
Antibodies were purchased as follows: p65 NF!B, I!B", phospho and total ERK, 
MKP-2, and IKK# from Santa Cruz  Biotechnology (CA, USA) ; phospho-p38 and -
JNK from Invitrogen, Paisley UK; COX-2 from Cayman Chemicals (Michigan, 
USA); anti-human VCAM-1 and ICAM-1 from R & D systems (Abingdon, UK); 
H2AX (Ser-139) from Upstate Biotechnology Inc, (Lake Placid, NY,USA); Cleaved 
Caspase-3 from Cell Signalling Biotechnology Inc, (Beverly, MA); FITC anti-Rabbit 
and HRP-conjugated secondary antibody from Jackson Immuno Research laboratories 
Inc. (West Grove, PA, USA).  
 
Cell culture 
Cryopreserved primary HUVECs were purchased from Lonza (Slough UK), and were 
grown in endothelial basal media (EBM-2), supplemented with endothelial growth 
media (EGM-2 Lonza, Slough, UK) containing single aliquots of defined supplements 
(2% foetal bovine serum, 0.2 ml hydrocortisone, 2 ml rhFGF-B, 0.5 ml VEGF, 0.5 ml 
R
3
-insulin like growth factor-1, 0.5 ml ascorbic acid, 0.5 ml rhEGF, 0.5 ml GA-1000 
and 0.5 ml heparin (concentrations not disclosed by the company). Cells were 
incubated at 37˚C in humidified air with 5% CO2.  All experiments were performed 
between passages 2 and 5.  
 
Adenoviral infections  
An adenoviral vector encoding dominant negative IKK# (Adv.DN-IKK#) and MKP-2 
(Adv. MKP-2) were created in-house using the Adeno-X virus purification kit from 
Clontech laboratories, Inc (CA, USA). The DN-IKK# plasmid was originally a gift 
from Dr D. Goeddel (Tularik Inc., CA, USA).  Large-scale production of high titre 
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recombinant adenovirus was performed by routine methods (Nicklin et al., 2004) 
HUVECs, when approximately 50-60% confluent, were incubated with adenovirus up 
to 300p.f.ucell
-1
 for 40 h in endothelial growth media.  Cells were stimulated with 
agonist for the indicated times in complete medium.  
 
 
 
 
Western blotting 
Proteins (15µg) were separated by either 8.5% or 10% SDS–PAGE and transferred 
onto nitrocellulose. The membranes were blocked for non-specific binding for 2 h in 
2% BSA (w:v) diluted in NATT buffer (20 mM Tris, 150 mM NaCl, 0.2% (v:v) 
Tween-20, pH 7.4). Membranes were then incubated overnight with primary antibody 
diluted in 0.2% BSA (w:v) in NATT buffer at room temperature. The membranes 
were then washed with NATT buffer for 90 min and incubated with HRP-conjugated 
secondary antibody for 2 h. After a further 90 min wash, the membranes were 
subjected to ECL reagent and exposed to Kodak X-ray film for appropriate time. 
 
JNK activity 
Cells were stimulated as appropriate and the reaction terminated by rapid aspiration 
and the addition of ice-cold PBS. The cells were solubilised in 20 mM HEPES buffer, 
pH 7.7, containing 50 mM NaCl, 0.1 mM EDTA, 0.1mM Na3VO4, 0.1 mM PMSF, 10 
µg ml
-1
 aprotinin, 10 µg ml
-1
 leupeptin, and 1% (w/v) Triton X-100. Lysates were 
clarified by centrifugation for 5 min at 13,000 rpm and equal amounts of protein were 
incubated with 20 µg of GST-c-Jun-(5–89) immobilized on glutathione-Sepharose at 
4°C for 3 h. Beads were then washed three times in solubilisation buffer and twice in 
25 mM HEPES buffer, pH 7.6, containing 20 mM #-glycerophosphate, 0.1 mM 
NaV3O4 and 2mM dithiothreitol. Precipitates were then incubated with the same 
buffer containing 25 µM/0.5 µCi of ATP/ [$-
32
P] ATP in a final volume of 30 µl at 30 
°C for 30 min. The reactions were terminated by the addition of 4 x SDS-sample 
buffer and aliquots of each sample subjected to electrophoresis on 11% SDS-
polyacrylamide gel electrophoresis. Phosphorylation of GST-c-Jun was then 
determined by autoradiography.  
 
 
Immunofluorescence 
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HUVECs were grown to 50-60% confluency on No.0 glass cover slips (Merck 
Biosciences, Nottingham, England). After adenovirus infection (40 h) cells were 
washed 3x with ice-cold phosphate-buffered saline (PBS) prior to fixation with 1 ml 
of 3% paraformaldehyde solution. Cover slips were then incubated with 0.1% triton 
X-100 in PBS for 5 min at room temperature. Cover slips were washed 3 times in 
PBS and 3 times with 1% BSA diluted in PBS (w:v) for 5 min followed by incubation 
with primary monoclonal MKP-2 antibody (1:200 in 1% BSA) for 1 h. Again cover 
slips were washed with ice cold PBS and incubated with secondary monoclonal 
antibody (1:400 in 1% BSA) mixed with 100 ngml
-1
 of DAPI for 45 min. Following 
three washes with ice cold PBS, Mowiol was used to mount cover slips onto slides for 
visualization by EP-1 fluorescence light microscopy.  
 
Flow cytometry assay of apoptosis 
Cells were infected for 40 h then stimulated for a further 24 h prior to analysis.  Cells 
were trypsinised and then pelleted at 1000 rpm for 2 min.  The pellet was then 
resuspended in 500µl of 1x annexin binding buffer (10 mM Hepes/NaOH, pH 7.4, 
140 mM NaCl and 2.5 mM CaCl2).  Phycoerthyrin-Annexin V and 7-AAD were 
added to the cells according to the manufacturer’s instructions and the samples were 
read in the FACS scan flow cytometer using FACS Diva software (FACS scan, 
Becton Dickinson, Oxford, UK).  The data was analysed using FACS Diva (Becton 
Dickinson, Oxford, UK) and RCS Express (De Novo Software, Canada) software.  A 
total of 10,000 events were measured per sample. Gating was determined using PE-
Annexin V FL-2 and 7–AAD FL-3 standards attached to beads (Becton Dickinson, 
Oxford, UK) and preliminary experiments conducted using paraformaldehyde and 
serum deprivation to define apoptotic and necrotic populations as outlined by the 
manufacturer’s instructions.  
 
Data analysis 
Each figure represents one of at least four separate experiments.  Western blots were 
scanned on a Epson perfection 1640SU scanner using Adobe photoshop 5.0.2 
software. For gels, densitometry measurement was performed using the Scion Image 
program. Data were expressed as mean ± s.e.m.  Statistical analysis was performed by 
One-way ANOVA with Dunnett’s Post test (*p<0.05, **p<0.01, ***p<0.001).  
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Results 
The effect of adenoviral infection with MKP-2 (Adv.MKP-2) on tumour necrosis 
factor alpha (TNF!)-stimulated JNK activation was assessed in HUVECs (Figure 1).  
Imunofluorescent staining (Panel A) showed no endogenous MKP-2 expression in 
LacZ-infected control cells, however following Adv.MKP-2 infection at a maximum 
concentration of 300 m.o.i., greater than 95% of the cells stained for nuclear MKP-2.  
Under these conditions, Adv.MKP-2 caused a significant inhibition of JNK 
phosphorylation, stimulated by TNF! (20 ngml
-1
), the response being virtually 
abolished at 200-300 p.f.u.cell
-1
 (Panel B, fold stimulation: TNF! = 24.4 ± 4.5, TNF! 
+ Adv.MKP-2 (300 p.f.u.cell
-1
) = 1.6 ± 0.3, P<0.01).  Both p46 and p54 isoforms 
were similarly affected. Adv.MKP-2 also reduced TNF! -stimulated JNK in vitro 
kinase activity (Panel C, P<0.01 compared to TNF! stimulation) and phosphorylation 
of c-Jun, an immediate downstream target of JNK (Panel D, P<0.01). 
 We also examined ERK and p38 MAP kinase phosphorylation to confirm that 
the effect of MKP-2 was specific to JNK signalling (Figure 2).  TNF! stimulated 
ERK phosphorylation was maximal at 15- 30 min, 2-3 fold of basal values. Neither 
this response, or basal levels, were affected by MKP-2 infection up to 300 p.f.u.cell
-1
 
(panel A).  TNF! stimulated a substantial increase in p38 MAP kinase 
phosphorylation however, this response was not significantly affected by Adv.MKP-2 
infection (Panel B).  
We next sought to determine if by a selective effect upon JNK, MKP-2 was 
able to regulate the expression of ICAM, VCAM and COX-2 (Figure 3).  For both 
ICAM and VCAM, infection with 300 p.f.u.cell
-1
 of Adv.MKP-2 had no inhibitory 
effect upon TNF! stimulated induction and in fact, a minor non-significant 
enhancement of both ICAM and VCAM expression could be observed (Panels A & 
B). In contrast, TNF!-induced COX-2 expression was significantly reduced following 
infection with Adv.MKP-2 (Panel C, % inhibition = 99.66 ± 0.2, P<0.001).  A similar 
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finding was also observed for HUVECs stimulated with LPS (not shown) suggesting 
that the effect of MKP-2 was not agonist-dependent.   
Studies suggest that in HUVECs, COX-2, ICAM and VCAM are regulated by 
NF"B signalling, so we sought to assess possible synergy effects of MKP-2 over-
expression and NF"B inhibition (Figures 4-6).  Initially, we utilised a adenoviral 
dominant negative form of inhibitory kappa B kinase # (DN-IKK#) a kinase which 
plays a key role in regulating NF"B (Gomez et al., 2005; MacKenzie et al., 2007).  
We demonstrated that infection of HUVECs with 300 p.f.u.cell
-1
 of DN-IKK# 
resulted in a substantial, almost complete inhibition of the expression of all three 
proteins induced in response to TNF! (Figure 4). Conditions were then established to 
allow simultaneous infection with both viruses and we then assessed the effects of the 
two interventions in combination (Figures 5 & 6).  We found that for COX-2 (Figure 
5), Adv.DN-IKK# and Adv.MKP-2 infection alone substantially reduced protein 
expression (% inhibition; Adv.MKP-2 = 88.3 ± 0.11, Adv.DN-IKK# = 64.52 ± 8.94). 
In combination the inhibition was not significantly greater (% inhibition 98.0 ± 3.2%) 
than for either agent alone.  For ICAM and VCAM however, the situation was 
markedly different (Figure 6).  Whilst DN-IKK# substantially reduced ICAM and 
VCAM, co-expression of MKP-2 was able to almost completely reverse this 
inhibition, expression of both proteins where similar to LacZ controls.  As shown 
previously, MKP-2 alone did not significantly affect ICAM or VCAM expression. 
Control Western blotting also indicated that the reversal was not due to an inhibitory 
effect of MKP-2 upon DN-IKK# expression nor vice versa, neither protein was 
affected by infection with the other adenovirus.  
 The potential for MKP-2 to influence NF"B-dependent gene expression was 
further examined at the level of NF"B signalling (Figure 7).  Pre-incubation with 
Adv. MKP-2 had a minor effect upon basal I"B! levels in HUVECs, however 
infection with Adv.MKP-2 was able to markedly potentiate submaximal TNF!-
induced I"B! loss (Panel A).  As expected pre-incubation with DN-IKK# partially 
reversed the agonist-stimulated I"B! loss, however, further infection with Adv.MKP-
2 restored the loss. Individual expression of MKP-2 and DN-IKK# was not influenced 
by co-infection and LacZ at higher concentrations (600 p.f.u.cell
-1
) did not mimic the 
effects of the combination, suggesting a bona fide effect of Adv. MKP-2.   
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 We also examined the potential for MKP-2 to reverse endothelial cell 
apoptosis (Figure 8).  We adopted the strategy to use TNF! in combination with 
DNIKK# not only to mirror conditions for ICAM and VCAM expression but because 
inhibition of NF"B signalling is a requisite in most cell types, including endothelial 
cells, for TNF! induced apoptosis.  Cells stimulated alone with TNF! alone showed a 
minor, insignificant increase in apoptosis (% apoptosis; control = 1.73 ± 1.23, TNF! 
= 5.23 ± 1.04, ns).  However, in the presence of DN-IKK# apoptosis was marked, 
rising to 28.23 ± 7.15 %.  (Panels A & B).  Co-expression of MKP-2 significantly 
reversed cell death by approximately 50% (% apoptosis +Adv.MKP-2 = 14.26 ± 4.86, 
p<0.05). Again control Western blotting demonstrated no difference in relative 
expression of either DN-IKK# or MKP-2 alone or in combination at this longer time 
point (Panel C).    
 Finally we sought to confirm that MKP-2 reversal may have an effect upon 
JNK regulated nuclear proteins involved in regulating apoptosis and nuclear damage 
(Figure 9).  TNF! alone gave a minor increase in the phosphorylation of H2AX a 
nuclear histone 2A family protein, whilst in combination DN-IKK# phosphorylation 
was markedly increased (Panel A, fold simulation; TNF!/ DN-IKK# = 12.33±2.36). 
We found that Adv.MKP-2 was able to reverse TNF!/DN-IKK#-mediated 
phosphorylation of H2AX (Fold stimulation; TNF!/DN-IKK# + Adv.MKP-2 = 3.64 
± 0.47, P<0.05).  As an additional negative control we also assessed the formation of 
cleaved caspase-3 products p19 and p17, pro-apoptotic proteins generated in the 
cytosol (Panel B).  To our surprise however, we found that MKP-2 over-expression 
resulted in a complete reversal of caspase-3 cleavage stimulated again by TNF! in 
combination with DN-IKK#. 
 
 
 
 
 
 
 
 
 
 11 
 
 
 
 
 
 
 
 
Discussion 
In this study we utilised a dual specific nuclear phosphatase, MKP-2, as an 
experimental pharmacological tool to reverse JNK mediated responses in HUVECs 
and thus determine its potential use in clinical conditions involving endothelial cell 
dysfunction. At the cellular level our studies reveal a novel point of cross talk 
between MKP-2 and the NF"B signalling pathway.  We also found that MKP-2 over-
expression can inhibit apoptosis and that this effect correlated not only with the 
dephosphorylation of the pro-apoptotic histone protein H2AX, but with caspase-3 
degradation, a cytosolically mediated event, despite MKP-2 being a nuclear 
phosphatase.  This unique combination of effects suggests that Adv.MKP-2 could 
represent a novel experimental approach for future treatment of cardiovascular disease 
in which endothelial cell apoptosis is a feature.   
Initially, we demonstrated that HUVECs infected with Adv MKP-2 resulted in 
the expression of a 42 KDa protein and as assessed by immunofluorescence, a protein 
strictly targeted to the nucleus (Sloss et al., 2005).  Previous studies have shown that 
HUVECS express MKP-2 protein endogenously (Wadgaonkar et al., 2004) but no 
function was assigned for MKP-2 in endothelium. Under our conditions of culture we 
found no basal nor agonist induced expression of MKP-2. The lack of MKP-2 
expression, in contrast to rodent systems, is a common feature of human cellular 
studies and it is at present unclear as to what manipulations are required to promote 
protein expression.   Nevertheless, it allowed the use of Adv.MKP-2 without the 
potential of contaminating endogenous protein.  Our results clearly demonstrated a 
selective effect of MKP-2 over-expression, the abrogation of JNK phosphorylation 
(Figure 1). This finding is consistent with previous studies in our laboratory 
examining TNF! stimulation (Robinson et al., 2001) and genotoxic stress (Cadalbert 
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et al., 2005).   Studies in vitro show MKP-2 to be selective for JNK and ERK (Chu et 
al., 1996), lack of effectiveness against ERK following cellular stimulation may 
reflect the poor ERK stimulation in response to TNF!.   
 In our hands we found Adv.MKP-2 to be effective against the expression of 
COX-2, consistent with previous studies showing expression of this protein to be 
regulated by the JNK pathway (Nieminen et al., 2006; Nieminen et al., 2005; Wu et 
al., 2006).  By contrast, we found no inhibition of ICAM and VCAM a finding 
consistent with some but not all studies (De Cesaris et al., 1999; Kobuchi et al., 1999) 
suggesting cell type specific differences in the role of JNK in the regulation of 
adhesion molecule expression.  The predominant pathways regulating ICAM and 
VCAM in most cell types are p38 MAP kinase, which is not a substrate for MKP-2 
(Rahman et al., 2004; Yan et al., 2002), and also NF"B (Rahman et al., 1999).  
However, using MKP-2 we have identified, for the first time, the potential of JNK 
inhibition to enhance the expression of ICAM and VCAM, revealed only in 
conditions of partial NF"B inhibition. This effect was specific for ICAM and VCAM, 
COX-2 expression, despite also being NF"B-dependent, was also strongly reduced by 
Adv.MKP-2 alone and in combination with DN-IKK# did not show any reversal of 
inhibition. This suggests the potential for JNK to play a negative role in the 
expression of ICAM and VCAM. This phenomenon was implied from a single study 
by (Hosokawa et al., 2006) whereby pre-treatment with the JNK inhibitor SP600125 
resulted in slightly enhanced VCAM expression.  Indeed, preliminary results in our 
laboratory showed a similar phenomenon using SP600125 (not shown), indicating a 
JNK mediated effect.  However, in this study we extend the work and show this 
phenomenon to be correlated with an effect upon NF"B activation, MKP-2 was able 
to enhance TNF! induced I"B! loss or reverse the inhibitory effect of DN-IKK#.  
This present study is one of the few demonstrating that long term JNK down-
regulation can enhance NF"B activation (Sanchez-Perez et al., 2002).  
Overwhelmingly, studies indicate the reverse phenomenon, NF"B limits the kinetics 
of JNK signalling (Papa et al., 2006).    
We then determined if MKP-2 had an effect upon HUVEC apoptosis, a 
process also influenced by the interplay between NF"B and JNK signalling.  TNF! 
has been shown to be mediated apoptosis in HUVECs but only in certain conditions 
such as following cycloheximide pre-treatment or NF"B inhibition (Wadgaonkar et 
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al., 2004).  A number of studies have shown that in endothelial and other cell types 
NF"B is able to mediate cellular protection through the enhanced expression of a 
number of protective proteins including Gadd45b (De Smaele et al., 2001) and XIAP 
(Tang et al., 2001) which function to suppress JNK activation.  Recent studies have 
also shown that several antioxidant enzymes are under NF"B regulation and may also 
contribute to limiting JNK activity (Papa et al., 2006) by inhibiting ROS generation. 
Under conditions of NF"B inhibition, TNF! was indeed found to sustain JNK 
activation in HUVECs (not shown) and cause a significant increase in apoptosis, 
results consistent with previous findings in endothelial cells (Stehlik et al., 1998). 
MKP-2 significantly reversed apoptosis however the reversal was not total, 
suggesting the potential of both JNK -dependent and -independent pathways 
controlling apoptosis. A role for JNK in endothelial cell apoptosis has been previously 
established using pharmacological inhibitors (Fu, Yin et al. 2006; Karahashi, 
Michelsen et al. 2009) however, only one previous study has demonstrated that MKP-
2 can mediate the same inhibition of JNK and thus regulate cell death (Cadalbert et 
al., 2005).   
In investigating the correlation between reversal of cell death and effects upon 
pro-apoptotic proteins we made a series of novel observations.  Initially we found that 
TNF! in combination with DN-IKK# results in increased phosphorylation of H2AX,  
a histone protein involved in regulating cellular responses to DNA damage (Kinner et 
al., 2008).  Initial studies indicated that this protein, was regulated by PIKKs. 
(Fernandez-Capetillo et al., 2004), however our work suggests phosphorylation by 
JNK in agreement with a recent study in HeLa cells (Lu et al., 2006).  Interestingly, 
we also found that MKP-2 over-expression was also able to abolish the formation of 
cleaved caspase-3 proteins p19 and p17. Caspases are implicated in endothelial cell 
apoptosis mediated in response to TNF! (Daniel et al., 2004) and a number of 
stressful agents such as high glucose and hydrogen peroxide (Ho et al., 2000; 
Ramachandran et al., 2002).  In some of these models caspase-3 cleavage is regulated 
by JNK (Ho et al., 2000; Ramachandran et al., 2002). Translocation of caspase 
fragments is dependent upon prior cleavage of procaspase 3 in the cytosol and 
association with recognised substrates (Kamada et al., 2005).  Thus, as MKP-2 is 
strictly nuclear located, even at high
 
viral concentrations, this suggests that to regulate 
caspase-3 cleavage in endothelial cells, JNK must be firstly phosphorylated within the 
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nucleus prior to translocation to the cytosol.  Current dogma suggests roles for JNK 
both within the nucleus and mitochondria (Dhanasekaran et al., 2008) however, a 
functional link between each compartment has not been established.  Alternatively, it 
may be that a pool of MKP-2 is located in the mitochondria, as is the case with MKP-
1 (Rosini et al., 2004), and functions to directly regulate JNK activity within this 
compartment.  In addition is the possibility that long term down regulation of JNK has 
a rebound effect upon the expression of anti-apoptotic proteins such as cFLIP, 
(Albrecht et al., 2009; Suzuki et al., 2003) XIAP, (Tang et al., 2001) or A20 (Daniel 
et al., 2004).  
Overall, our studies have identified the potential for over-expression of MKP-
2 to down regulate JNK-dependent COX-2 expression and up regulate NF"B 
dependent expression of ICAM and VCAM.  We also show that MKP-2 is able to 
negate TNF! stimulated apoptosis by regulating not only nuclear events such as 
phosphorylation of H2AX but also cytosolic events such as caspase 3 cleavage.  Thus, 
Adv.MKP-2 has a potential therapeutic use in clinical conditions were JNK mediated 
effects upon endothelial apoptosis is a feature. A number of previous studies have 
already utilised adenovirus infection to express proteins such TIMP-3 and p53 to 
inhibit vascular remodelling in vitro (George et al., 2001; George et al., 1998a; 
George et al., 1998b) and in vivo (George et al., 2000).  Whilst these approaches are 
associated primarily with inhibiting smooth muscle cell migration and mediating 
apoptosis, other studies have delivered adenoviral eNOS to enhance re-
endothelialisation and inhibit restenosis (Sharif et al., 2008; Tanner et al., 2004).  
Thus, the anti-apoptotic effects of Adv.MKP-2 over-expression in endothelial cells 
may be a useful outcome which can be exploited in vivo.  It will be complicated 
however, by effects upon adhesion molecule expression which may enhance 
migration of macrophages to the sub-endothelial space.  This may limit its clinical 
use.  
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Figures 
 
Figure 1. Adv.MKP-2 expression inhibits TNF!-stimulated JNK 
phosphorylation and activation in HUVECs.   
HUVECs were infected with 300 p.f.u.cell
-1
 of Adv.MKP-2 or Lac Z (Panels A, C 
and D) or increasing concentrations as indicated (Panel B) for 40 h prior to 
stimulation with TNF! for a further 30 min (Panels B-D).  In panel A cells were 
stained for MKP-2 expression. Samples were also assessed for phospho-JNK (Panel 
B) JNK activity (panel C) and phospho-c-Jun content (Panel D) as outlined in the 
Methods section.  Results from gels were quantified using scanning densitometry.  
Each value represents the mean ± SEM of at least 4 experiments. ***P<0.001 
compared to TNF! stimulation alone. 
 
Figure   2.  Effect of Adv.MKP-2 expression on TNF!-stimulated ERK or p38 
MAP kinase phosphorylation   
HUVECs were infected with 300 p.f.u.cell
-1
 of Adv.MKP-2 or LacZ control for 40 h 
prior to stimulation with TNF! for a further 30 min.  Samples were assessed for 
phospho-ERK (Panel A) and phospho-p38 MAP kinase (Panel B) as outlined in the 
Methods section.  Results from gels were quantified using scanning densitometry.  
Each value represents the mean ± SEM of at least 4 experiments. Ns –not significant 
compared to TNF! stimulation alone. 
 
Figure  3.  Differential effect of Adv.MKP-2 on TNF!-stimulated ICAM and 
VCAM and COX-2 expression in HUVECs 
HUVECs were infected with 300 p.f.u.cell
-1
 of Adv.MKP-2 or LacZ control for 40 h 
prior to stimulation with TNF! for a further 24 h.  Samples were assessed for MKP-2 
levels, ICAM (Panel A), VCAM (Panel B) or COX-2 (Panel C) by Western blotting. 
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Results from gels were quantified using scanning densitometry. Each value represents 
the mean ± SEM of at least 4 experiments. ***P<0.001 compared to agonist 
stimulation alone. 
 
 
Figure   4. Inhibition of NF"B signalling inhibits TNF!-stimulated ICAM, 
VCAM and COX-2 expression in HUVECs.  
HUVECs were infected with 300 p.f.u.cell
-1
 Adv.DN-IKK# or lacZ control for 40 h 
prior to stimulation with TNF! for a further 24 h.  Samples were assessed for ICAM 
(Panel A), VCAM (Panel B) and COX-2 (Panel C).  Results from gels quantified 
using scanning densitometry. Each value represents the mean ± SEM of at least 4 
experiments.  **P<0.01  and ***P<0.001  compared to agonist stimulation alone. 
 
Figure   5.  Combined effect of DN-IKK# and MKP-2 co-expression on TNF!-
stimulated COX-2 induction in HUVECs. 
HUVECs were infected with 300 p.f.u.cell
-1
 Adv.DN-IKK# or Adv.MKP-2 alone or 
in combination for 40 h prior to stimulation with TNF! for a further 24 h. Samples 
were assessed for COX-2 expression (Panel A) as outlined in the Methods section.   
Gels were quantified by densitometry (Panel B) and each value represents the mean ± 
S.E.M. from four experiments. *P<0.05 and **P<0.01 compared to agonist 
stimulation alone, ns-not significant compared to $dv.%&P-2 inhibition. 
 
Figure  6.  MKP-2 co-expression reverses DN-IKK#
 
inhibition of ICAM and 
VCAM expression in TNF!-stimulated HUVECS.   
HUVECs were infected with 600 p.f.u.cell
-1
 Lac Z, 300 p.f.u.cell
-1
 Adv.DN-IKK# or 
Adv.MKP-2 alone or in combination for 40 h prior to stimulation with TNF! for a 
further 24 h. Samples were assessed for ICAM or VCAM expression (Panel A) as 
outlined in the Methods section.  Data from blots where quantified by densitometry 
(Panel B) and each value represents the mean ± S.E.M. of at least four experiments. 
*P<0.05 compared to agonist stimulation alone, ns-not significant compared to either 
control or Adv.MKP-2 inhibition. 
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Figure  7.  MKP-2 expression reverses DN-IKK#
 
inhibition of TNF!  - stimulated 
I"B!  loss in HUVECs.  
HUVECs were infected with 600 p.f.u.cell
-1
 Lac Z, or 300 p.f.u.cell
-1
  Adv.DN-IKK#
 
or Adv.MKP-2 alone or in combination for 40 h prior to stimulation with TNF! 
(1ngml
-1
) for a further 30 min. Samples were assessed for I"B! or total p65 NF"B 
expression as outlined in the Methods section.  Each blot is representative of three 
others. Data from blots where quantified by densitometry (Panel B) and each value 
represents the mean ± S.E.M. of four experiments. *P<0.01 compared to TNF!/DN-
IKK# alone. +P<0.05 compared to %&P'2 inhibition.  
 
Figure  8.  Adv.MKP-2 infection reverses TNF!-mediated apoptosis in 
HUVECS. 
HUVECs were infected with 600 p.f.u.cell
-1
 Lac Z, or 300 p.f.u.cell
-1
 Adv. DN-IKK#
 
or Adv.MKP-2 alone or in combination for 40 h prior to stimulation with TNF! for a 
further 24 h.  Samples where assessed for Annexin V and 7-AAD staining as outlined 
in the Methods section (Panels A & B) whilst in parallel control experiments cell 
samples were Western blotted for IKK# and MKP-2 expression (Panel C).  In Panel B 
each value represents the mean ± S.E.M. of at least 4 experiments. *P<0.05 compared 
to TNF!/DN-IKK# stimulation alone. 
 
Figure 9.  MKP-2 over-expression reverses TNF!-induced H2AX 
phosphorylation and caspase-3 cleavage in HUVECs.    
HUVECs were infected with either 600 p.f.u.cell
-1
 Lac Z, or 300 p.f.u.cell
-1
 Adv.DN-
IKK#
 
or Adv.MKP-2 alone or in combination for 40 h prior to stimulation for a 
further 24 h.   Samples were assessed for phospho-H2AX (Panel A), caspase 3 (Panel 
B), IKK#, or MKP-2 expression as outlined in the Methods section.  Data from blots 
where quantified by densitometry.  Each value represents the mean ± S.E.M. of at 
least 4 experiments.  **P<0.01 compared to TNF!/DN-IKK# alone.  T-p38 
represents a loading control.   
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